Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
Filter
Medientyp
Sprache
Region
Bibliothek
Erscheinungszeitraum
Person/Organisation
Fachgebiete(RVK)
Zugriff
  • 1
    Online-Ressource
    Online-Ressource
    Cham :Springer International Publishing,
    UID:
    edoccha_BV047951549
    Umfang: 1 Online-Ressource (XVIII, 300 Seiten).
    Ausgabe: 1st edition
    ISBN: 978-3-030-86778-2
    Serie: Munich Studies on Innovation and Competition Volume 16
    Inhalt: This book draws a unique perspective on the regulation of access to clinical trial data as a case on research and knowledge externalities. Notwithstanding numerous potential benefits for medical research and public health, many jurisdictions have struggled to ensure access to clinical trial data, even at the level of the trial results. Pro-access policy initiatives have been strongly opposed by research-based drug companies arguing that mandatory data disclosure impedes their innovation incentives. Conventionally, access to test data has been approached from the perspective of transparency and research ethics. The book offers a complementary view and considers access to individual patient-level trial data for exploratory analysis as a matter of research and innovation policy. Such approach appears to be especially relevant in the data-driven economy where digital data constitutes a valuable economic resource. The study seeks to define how the rules of access to clinical trial data should be designed to reconcile the policy objectives of leveraging the research potential of data through secondary analysis, on the one hand, and protecting economic incentives of research-based drug companies, on the other hand. Overall, it is argued that the mainstream innovation-based justification for exclusive control over the outcomes of research and development can hardly rationalise trial sponsors' control over primary data from trials. Instead, access to such data and its robust analysis should be prioritised
    Weitere Ausg.: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-86777-5
    Weitere Ausg.: Erscheint auch als Druck-Ausgabe ISBN 9783030867799
    Weitere Ausg.: Erscheint auch als Druck-Ausgabe ISBN 9783030867805
    Sprache: Englisch
    Fachgebiete: Rechtswissenschaft
    RVK:
    RVK:
    Schlagwort(e): Reproduktionsmedizin ; Embryo ; Schutz ; Forschung ; Biotechnologie ; Reproduktionsmedizin ; Recht ; Hochschulschrift
    URL: Volltext  (URL des Erstveröffentlichers)
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 2
    Online-Ressource
    Online-Ressource
    Cham :Springer International Publishing,
    UID:
    edocfu_BV047951549
    Umfang: 1 Online-Ressource (XVIII, 300 Seiten).
    Ausgabe: 1st edition
    ISBN: 978-3-030-86778-2
    Serie: Munich Studies on Innovation and Competition Volume 16
    Inhalt: This book draws a unique perspective on the regulation of access to clinical trial data as a case on research and knowledge externalities. Notwithstanding numerous potential benefits for medical research and public health, many jurisdictions have struggled to ensure access to clinical trial data, even at the level of the trial results. Pro-access policy initiatives have been strongly opposed by research-based drug companies arguing that mandatory data disclosure impedes their innovation incentives. Conventionally, access to test data has been approached from the perspective of transparency and research ethics. The book offers a complementary view and considers access to individual patient-level trial data for exploratory analysis as a matter of research and innovation policy. Such approach appears to be especially relevant in the data-driven economy where digital data constitutes a valuable economic resource. The study seeks to define how the rules of access to clinical trial data should be designed to reconcile the policy objectives of leveraging the research potential of data through secondary analysis, on the one hand, and protecting economic incentives of research-based drug companies, on the other hand. Overall, it is argued that the mainstream innovation-based justification for exclusive control over the outcomes of research and development can hardly rationalise trial sponsors' control over primary data from trials. Instead, access to such data and its robust analysis should be prioritised
    Weitere Ausg.: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-86777-5
    Weitere Ausg.: Erscheint auch als Druck-Ausgabe ISBN 9783030867799
    Weitere Ausg.: Erscheint auch als Druck-Ausgabe ISBN 9783030867805
    Sprache: Englisch
    Fachgebiete: Rechtswissenschaft
    RVK:
    RVK:
    Schlagwort(e): Reproduktionsmedizin ; Embryo ; Schutz ; Forschung ; Biotechnologie ; Reproduktionsmedizin ; Recht ; Hochschulschrift
    URL: Volltext  (URL des Erstveröffentlichers)
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 3
    Online-Ressource
    Online-Ressource
    Cham :Springer International Publishing,
    UID:
    almafu_BV047951549
    Umfang: 1 Online-Ressource (XVIII, 300 Seiten).
    Ausgabe: 1st edition
    ISBN: 978-3-030-86778-2
    Serie: Munich Studies on Innovation and Competition Volume 16
    Inhalt: This book draws a unique perspective on the regulation of access to clinical trial data as a case on research and knowledge externalities. Notwithstanding numerous potential benefits for medical research and public health, many jurisdictions have struggled to ensure access to clinical trial data, even at the level of the trial results. Pro-access policy initiatives have been strongly opposed by research-based drug companies arguing that mandatory data disclosure impedes their innovation incentives. Conventionally, access to test data has been approached from the perspective of transparency and research ethics. The book offers a complementary view and considers access to individual patient-level trial data for exploratory analysis as a matter of research and innovation policy. Such approach appears to be especially relevant in the data-driven economy where digital data constitutes a valuable economic resource. The study seeks to define how the rules of access to clinical trial data should be designed to reconcile the policy objectives of leveraging the research potential of data through secondary analysis, on the one hand, and protecting economic incentives of research-based drug companies, on the other hand. Overall, it is argued that the mainstream innovation-based justification for exclusive control over the outcomes of research and development can hardly rationalise trial sponsors' control over primary data from trials. Instead, access to such data and its robust analysis should be prioritised
    Weitere Ausg.: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-86777-5
    Weitere Ausg.: Erscheint auch als Druck-Ausgabe ISBN 9783030867799
    Weitere Ausg.: Erscheint auch als Druck-Ausgabe ISBN 9783030867805
    Sprache: Englisch
    Fachgebiete: Rechtswissenschaft
    RVK:
    RVK:
    Schlagwort(e): Reproduktionsmedizin ; Embryo ; Schutz ; Forschung ; Biotechnologie ; Reproduktionsmedizin ; Recht ; Hochschulschrift
    URL: Volltext  (URL des Erstveröffentlichers)
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 4
    Buch
    Buch
    Cham, Switzerland : Springer
    UID:
    gbv_1782164421
    Umfang: xviii, 300 Seiten
    ISBN: 9783030867775 , 3030867773
    Serie: Munich studies on innovation and competition volume 16
    Anmerkung: Dissertation Universität Augsburg 2021
    Weitere Ausg.: ISBN 9783030867782
    Weitere Ausg.: Erscheint auch als Online-Ausgabe Kim, Daria Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law Cham : Springer International Publishing, 2021 ISBN 9783030867782
    Sprache: Englisch
    RVK:
    Schlagwort(e): Hochschulschrift
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 5
    Online-Ressource
    Online-Ressource
    Cham : Springer International Publishing
    UID:
    b3kat_BV047951549
    Umfang: 1 Online-Ressource (XVIII, 300 Seiten)
    Ausgabe: 1st edition
    ISBN: 9783030867782
    Serie: Munich Studies on Innovation and Competition Volume 16
    Inhalt: This book draws a unique perspective on the regulation of access to clinical trial data as a case on research and knowledge externalities. Notwithstanding numerous potential benefits for medical research and public health, many jurisdictions have struggled to ensure access to clinical trial data, even at the level of the trial results. Pro-access policy initiatives have been strongly opposed by research-based drug companies arguing that mandatory data disclosure impedes their innovation incentives. Conventionally, access to test data has been approached from the perspective of transparency and research ethics. The book offers a complementary view and considers access to individual patient-level trial data for exploratory analysis as a matter of research and innovation policy. Such approach appears to be especially relevant in the data-driven economy where digital data constitutes a valuable economic resource. The study seeks to define how the rules of access to clinical trial data should be designed to reconcile the policy objectives of leveraging the research potential of data through secondary analysis, on the one hand, and protecting economic incentives of research-based drug companies, on the other hand. Overall, it is argued that the mainstream innovation-based justification for exclusive control over the outcomes of research and development can hardly rationalise trial sponsors' control over primary data from trials. Instead, access to such data and its robust analysis should be prioritised
    Weitere Ausg.: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-86777-5
    Weitere Ausg.: Erscheint auch als Druck-Ausgabe ISBN 9783030867799
    Weitere Ausg.: Erscheint auch als Druck-Ausgabe ISBN 9783030867805
    Sprache: Englisch
    Fachgebiete: Rechtswissenschaft
    RVK:
    RVK:
    Schlagwort(e): Deutschland ; Reproduktionsmedizin ; Embryo ; Schutz ; Forschung ; Biotechnologie ; Deutschland ; Reproduktionsmedizin ; Recht ; Hochschulschrift
    URL: Volltext  (URL des Erstveröffentlichers)
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Meinten Sie 303086777?
Meinten Sie 3030767973?
Meinten Sie 3630867073?
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie auf den KOBV Seiten zum Datenschutz